Allogene Therapeutics, Inc. 8-K

What Happened

• Allogene Therapeutics, Inc. (ALLO) filed a Form 8-K on March 12, 2026 under Item 2.02 to provide a corporate update and announce its financial results for the fourth quarter and year ended December 31, 2025. The company’s press release containing the results is attached as Exhibit 99.1 to the filing. The 8-K is signed by President and CEO David Chang, M.D., Ph.D.

Key Details

• Filing date: March 12, 2026 (Form 8-K).
• Period covered: fourth quarter and full year ended December 31, 2025.
• Disclosure type: Item 2.02 — Results of Operations and Financial Condition; press release included as Exhibit 99.1.
• Authorized signature: David Chang, M.D., Ph.D., President and Chief Executive Officer.

Why It Matters

• This filing signals Allogene has released its latest quarterly and year-end earnings and a corporate update; those results contain the financial metrics (revenue, expenses, cash position, and operational updates) investors use to assess near-term performance and runway. The press release (Exhibit 99.1) is the source for the specific figures and management commentary—investors should review it to see revenue, earnings/loss, cash balance, and any program or guidance updates.